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Introduction
Chronic myeloproliferative disorders (MPDs), first pro-
posed by Dameshek in 1951, are clonal hematopoietic
stem cell disorders characterized by proliferation of 1
or more myeloid cell lineages in the bone marrow and
increased numbers of mature and immature cells in
peripheral blood.1 According to the World Health
Organization classification, MPDs include polycythemia
vera (PV), essential thrombocythemia (ET), idiopathic
myelofibrosis (IMF) and chronic myeloid leukemia
(CML), plus rarer subtypes such as chronic neutrophilic
leukemia, hypereosinophilic syndrome and chronic
eosinophilic leukemia. These diseases overlap with
myelodysplastic/myeloproliferative diseases such as
atypical CML and chronic myelomonocytic leukemia,
in which proliferation is accompanied by dysplastic
features or ineffective hematopoiesis in other line-
ages.2 The clinical pictures of these disorders share
many features: genesis in a single, multipotent hema-
topoietic stem cell that assumes dominance over non-
transformed progenitors; hypercellularity of the marrow,
with apparently unstimulated overproduction of 1 or
more of the formed elements of blood; and increased
risk of thrombosis and bleeding, spontaneous trans-
formation to acute leukemia and marrow fibrosis.3
Molecular Pathogenesis of 
Chronic MPDs
During the past 5 decades, many achievements have
been made in understanding the pathogenesis of PV,
ET and IMF. Both PV and ET are characterized by
increased sensitivity of committed hematopoietic cells
to their respective primary humoral growth factors:
erythroid precursors to erythropoietin (Epo) in PV
and megakaryocytes to thrombopoietin (Tpo) in ET.
In vitro, Epo-independent (endogenous) erythroid
colony formation and also Tpo-independent megakary-
ocyte colony formation are found in both PV and ET.4
However, no mutations of Epo and Tpo or their respec-
tive receptors, Epo-R and Tpo-R, have yet been iden-
tified in PV and ET. Moreover, subsequent studies
revealed that marrow and blood cells from patients
with PV were hypersensitive not only to Epo or Tpo
but also to several other hematopoietic growth factors,
including interleukin 3 (IL-3), stem cell factor (SCF),
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granulocyte-macrophage colony-stimulating factor
(GM-CSF) and insulin-like growth factor-1 (IGF-1).5–8
These findings suggest that events downstream from
receptor engagement might be responsible for endoge-
nous erythroid colony formation in PV or ET.
The Janus kinase (JAK)/signal transducers and
activators of transcription (STAT) pathway plays a cen-
tral role in initiating signal transduction from hemato-
poietic growth factor receptors. JAK2, like the other
members of the JAK family, has an enzymatically active
kinase domain (JAK homology 1 [JH1]) and a catalyt-
ically inactive pseudokinase domain (JH2). The JH2
domain has an autoinhibitory function that normally
suppresses the kinase activity of JAK2.9 A previous study
has demonstrated that inhibitors of JAK2 can repress
the Epo-independent differentiation of erythroid pro-
genitors in PV, and constitutive activation of STAT3
has also been reported in patients with PV.10 JAK2
therefore represented a logical target for identifying 
the molecular abnormalities of PV and ET.11 In 2005,
JAK2 V617F mutation was identified in patients with
chronic MPDs by using different approaches.12–15
James et al found that a kinase inhibitor of JAK2 or
knockdown of JAK2 (wildtype) expression using
small interfering RNA technology could inhibit the
formation of Epo-independent erythroid colonies that
are a hallmark of PV.12 This led to the sequencing of
JAK2 and the detection of a mutation in the JH2
pseudokinase domain of the JAK2 gene. However,
Kralovics et al had previously identified loss of het-
erozygosity of a region on chromosome 9p in PV and
identified a 6.2-Mbp region common to all of the 51
patients who were screened. As this region contained
JAK2, with its known role in erythropoiesis, this was
screened further for mutations.13 Three other groups
targeted JAK2 as part of a general sequencing screen
of tyrosine kinases and phosphatases in MPDs.14–16 As
shown in Table 1, all of the recently published studies
showed that the majority of patients with PV (65–97%)
have the JAK2 V617F mutation. In contrast, only
23–57% of patients with ET have the JAK2 muta-
tion.11,12,14–16 Our group reported that the frequency
of JAK2 V617F mutation could be detected in 81%,
61% and 33% of Taiwanese patients with PV, ET and
IMF, respectively.17 The mutation is somatic and has
not been detected in any normal individuals or patients
with secondary erythrocytosis. The mutation was also
rarely detected in patients with myelodysplastic syn-
drome, in patients with acute myelogenous leukemia
with or without antecedent PV or IMF, or in patients
with lymphoid leukemia.18–20 The differences in
reported rates are likely due to at least 3 reasons: (1)
the stringency of the criteria used to diagnose PV; 
(2) the sensitivity of the method used to detect muta-
tions; and (3) the source of DNA. Direct sequencing
techniques are used in the detection of JAK2 V617F
mutation in most studies. However, they are likely to
have a lower sensitivity than techniques that employ
polymerase chain reaction (PCR) amplification of the
mutant allele, such as allele-specific PCR or amplifica-
tion refractory mutation system PCR.21 The majority
of studies have used peripheral blood neutrophils, as
they are thought to be derived from the same clonal
progenitor that is transformed in PV. The JAK2
V617F mutation has been detected in progenitors and
myeloid cells including cells with hematopoietic stem
cells, common myeloid progenitor and megakaryocyte–
erythroid progenitor phenotypes as well as colony-
forming cells and more mature progenies, such as
neutrophils and platelets.15,22,23 So far, mutant JAK2
V617F has not been reported in T or B lympho-
cytes.12,24 The JAK2 V617F mutation is a gain-of-
function mutation in that it releases the autoinhibitory
action of JH2 and thereby results in expression of a
constitutively activated JAK2 tyrosine kinase. JAK2
V617F may thus bind to a receptor (e.g. Epo-R or
Tpo-R) and recruit STATs in the absence or in the
presence of only trace quantities of hematopoietic
growth factor (e.g. Epo or Tpo). An in vitro study has
demonstrated that the expression of the mutated
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Table 1. Frequency of JAK2 V617F mutation in chronic myeloproliferative disorders
Study Polycythemia, n (%) Essential thrombocythemia, n (%) Idiopathic myelofibrosis, n (%)
James et al12 40/45 (89) 9/21 (43) 3/7 (43)
Kralovics et al13 83/128 (65) 21/93 (23) 13/23 (57)
Levine et al14 121/164 (74) 37/115 (32) 16/46 (35)
Baxter et al15 71/73 (97) 29/51 (57) 8/16 (50)
Zhao et al16 20/24 (83)
Hsu et al17 25/31 (81) 23/38 (61) 2/6 (33)
Jones et al18 58/72 (81) 24/59 (41) 15/35 (43)
Total 418/537 (77) 143/377 (37) 57/133 (42)
JAK2 (but not wildtype JAK2) induced Epo hyper-
sensitivity and Epo-independent survival of cultured
cell lines.12 Clinical study also confirmed that the
presence of the JAK2 V617F mutation is correlated with
other biological phenomena such as polycythemia rubra
vera-1 (PRV-1) expression and endogenous erythroid
colony formation.25,26 A small interfering RNA
(siRNA), used to knockdown JAK2 expression, can
further block endogenous erythroid colony formation
in the cells from PV patients with the JAK2 V617F
mutation.12 The in vivo effect of the mutation was
demonstrated by the development of erythrocytosis in
mice that received transplants with bone marrow con-
taining the JAK2 V617F mutation, but not wildtype
JAK2.12 Recently, Kralovics et al26 further demon-
strated that the alterations in the expression of the bio-
logical and epigenetic markers in patients with PV and
ET, including deregulated expression of Bcl-x, an
inhibitor of apoptosis, overexpression of the PRV-1
and transcription factor NF-E2 genes and impaired
expression of Tpo-R26–30 are due to the activation of
the JAK/STAT pathway through the JAK2 V617F
mutation. This evidence strongly indicates that the
JAK2 V617F mutation has a direct causative role in
the pathogenesis of MPDs.
However, several questions remain unanswered: 
(1) how might a single mutation give rise to at least 3
different diseases (PV, ET and IMF) and also to some
other atypical MPDs; and (2) why don’t all patients
demonstrate this mutation? In a recent study, Campbell
et al demonstrated that V617F mutation-positive ET
patients had multiple features resembling PV, with sig-
nificantly increased hemoglobin, neutrophil counts,
bone marrow erythropoiesis and granulopoiesis, more
venous thromboses and a higher rate of PV transforma-
tion than those without the mutation.31 V617F muta-
tion-positive ET patients also had lower serum Epo
and ferritin concentrations than did mutation-negative
patients.31 Nonetheless, V617F mutation-negative ET
patients did show many clinical and laboratory features
that were characteristic of MPDs, including cytogenetic
abnormalities, hypercellular bone marrow with abnor-
mal megakaryocyte morphology, PRV overexpression,
growth of Epo-independent erythroid colonies, and
risk of myelofibrotic or leukemic transformation.31 This
evidence implies that JAK2 V617F-positive ET and PV
form a biological continuum, with the degree of ery-
throcytosis determined by physiologic or genetic modi-
fiers.31 This model suggests that, in patients at the
thrombocythemia end of the continuum, the effects of
the V617F mutation on erythropoiesis are constrained
by physiologic mechanisms, including Epo suppression
and depleted iron stores, or by genetic modifiers,
either acquired or constitutional. Acquisition of homo-
zygosity for the V617F mutation may favor develop-
ment of a polycythemic phenotype since homozygosity
for mutant JAK2 occurs in approximately 30% of
patients with PV, but is rare in ET.12–15 Gender may
influence presentation of V617F-positive disease, since
PV is more common in men, whereas V617F-positive
thrombocythemia is more common in women.32,33
The animal model also suggests that genetic modi-
fiers affect the hematopoietic phenotype of the JAK2
mutation. A recent study has demonstrated that expres-
sion of JAK2 V617F in mouse bone marrow results in
polycythemia in different strains, but that associated
leukocytosis is strain-dependent.34 In those PV or ET
patients without JAK2 V617F mutation, disease alleles
other than JAK2 V617F might be involved, however,
Levine et al failed to identify any mutations by exon
sequence analysis of the activating loops and autoin-
hibitory domains of other tyrosine kinases in granulo-
cyte DNA samples from PV patients.14 Other mutations
may occur in pathways that interact with JAK/STAT
signaling or in other effector proteins, including adapter
molecules that facilitate JAK/STAT pathway activa-
tion.35 Mutations in any one of several known negative
regulators of the JAK/STAT pathway might be like-
wise operative in the other PV or ET patients without
JAK2 V617F mutation.
JAK2 V617F Mutation in the Diagnosis
and Treatment of PV and ET
This breakthrough discovery has had a great impact in
the diagnosis of chronic MPDs. In the newly proposed
diagnostic criteria for PV, presence of the JAK2 V617F
mutation has been integrated as a major criterion
(Table 2).36 It has been suggested that JAK2 V617F
mutation analysis can be used to help screen individuals
with polycythemia and that this may reduce the need
for further investigations, such as red cell mass and
bone marrow biopsy.24,37 However, the presence of 
a JAK2 V617F mutation alone does not distinguish
PV from IMF or ET.38 In ET, where differentiating a 
primary proliferative condition from a reactive one is
notoriously difficult, the use of JAK2 mutation analysis
may assist in identifying patients with a stem cell disor-
der. However, it has to be remembered that patients
without a JAK2 mutation can still have a primary MPD.
Recently, the Medical Research Council Primary
Thrombocythemia-1 Trial studied the effect of JAK2
V617F mutation on treatment outcome in patients
with ET and PV, demonstrating that JAK2 V617F
mutation-positive patients were much more sensitive
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to hydroxyurea, but not to anagrelide, than those with-
out the JAK2 V617F mutation.31 Furthermore, the
rate of arterial thrombosis appeared to be lower in
JAK2 V617F-positive patients receiving hydroxyurea
compared to those receiving anagrelide, an effect that
was not evident in JAK2 V617F-negative patients.31
These findings further support the concept of classifying
patients as JAK2 V617F-positive or -negative during
diagnosis and designing individualized treatment
strategies for PV or ET patients.
The identification of JAK2 V617F mutations in
MPDs has stimulated a great deal of effort in screen-
ing and developing specific inhibitors for clinical use.
It is certain that the next few years will bring further
developments in this fast-evolving field. However, as
the management of many PV patients with conventional
therapies such as phlebectomy, aspirin and hydroxyurea
has a reasonable outcome with little hematologic toxicity
and relatively modest costs, extensive evaluation of the
potential hematologic toxicity and a cost–benefit analy-
sis will be needed before inhibitors of the JAK signaling
pathway can be introduced into clinical practice, espe-
cially for MPD patients with the JAK2 V617F mutation.
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